Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$0.32
▼ $0.02 (-6.8%)
Market data updated: 09/30 01:13 PM
Fundamentals updated: 09/30/2026
News analyzed: 09/30/2026
Market Cap
$7.60M
Day Range
$0.31 - $0.35
52-Week Range
$0.29 - $2.57
Beta
—
Next Earnings
10.11.2026
Support
$0.29
Resistance
$0.96
TCRX is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
-81.7% (1Y)
Strengths: 11/30 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🔴 Bearish
Technical Trend
🔴 Bearish
Insiders
🟢 Bullish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Revenue growth (last year)
Revenue growth (last year): 266.7%
Growth
Biggest negative driver
Operating margin
Operating margin: -1315.4% (negative)
Fundamental
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
43
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
51
Quality
63
Value
55
Momentum
29
Risk
46
Sentiment
50
Fundamental
29
Institutional
100
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of TScan Therapeutics, Inc. has centered on its strategic shift and financial challenges. The company announced a refocus on in vivo cell therapy for solid tumors while pausing its Phase III hematology study, alongside reports of layoffs. Analysts from Wedbush and HC Wainwright downgraded the stock to *Neutral*, slashing price targets from $5–$7 to just $1, citing market concerns. Trading activity, including unusual volume and price gaps, also highlighted investor uncertainty.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about TScan Therapeutics, Inc.. News trend score: 50. Reason: The mix of positive and negative articles is balanced — 5 vs. 5 out of the last 20 articles.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
13
🎯 Conviction (vs. Emotion)
61
Psychology
100
Fundamentals
29
Technical
29
Valuation
55
A significant decline over time, but on unusually low trading volume — holders unwilling to accept the loss.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price (3M)
-70%
Market Narrative
43
Fundamental Reality
61
Narrative Gap
-18
🧠 StockIQ Psychologist
TCRX’s market behavior suggests a dominant panic-driven liquidation, amplified by extreme oversold conditions (RSI 17) and elevated volatility. The narrative gap (-28) hints at a disconnect where traders may overreact to short-term data, while fundamentals (EPS growth) remain detached. Loss aversion and anchoring coexist, with traders clinging near support but still selling aggressively. The key question: Will the 2.5% support hold, or will the 3.13x volume trigger a further cascade? Peer divergence (herding score 2) implies this is an isolated sell-off, not a systemic trend.
Updated: 09/09/2026, 09:19 AM
What could change this?
👥 What the crowd believes
"HC Wainwright & Co. downgrades TScan Therapeutics to Neutral, lowers price target to $1"
"redirects resources toward an in vivo-engineered T cell receptor (TCR-T) program targeting solid tumors"
"workforce reduction of approximately 75%"
📈 16D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Benjamin Graham — 100/100
🔴 Weakest match
Morgan Housel — 29/100
🗣️ Why do they disagree?
This stock splits methodologies into two starkly contrasting camps: the value and cycle-focused investors overwhelmingly see it as a compelling opportunity, while the growth, behavioral, and contrarian approaches either dismiss it or flag significant red flags. Benjamin Graham and his Enterprising Investor variant, along with Howard Marks (market cycle) and Samuel Nelson, all rate it as a near-perfect fit—highlighting its deep statistical discounts, favorable cycle positioning, and defensive appeal. Even Jack Schwager’s disciplined trading framework gives it a high score, suggesting a strong reward-to-risk profile. In contrast, Fisher, Veblen, and Livermore reject it outright: Fisher dismisses it for lacking his signature quality/growth traits, Veblen sees it as speculative growth-chasing, and Livermore’s trend-following rule outright penalizes it. The divide also extends to patient long-term holders like Smith (who approves) versus volatility-sensitive investors like Housel (who warns it could spook patient buyers). The efficient-market skeptics further muddy the waters, calling the case for active selection weak, leaving the stock as a rare example where value/cycle methodologies align in enthusiasm while growth and behavioral frameworks remain deeply skeptical.
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟢 100
Attractive to a Defensive Graham Investor
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 100
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟢 100
Deep statistical discount — a real Enterprising Investor candidate
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟢 100
Looks early-to-mid cycle, not overextended
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 85
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟢 79
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟢 78
Risk appears reasonably priced — no obvious cycle-timing red flag
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟢 76
A real, disciplined setup with favorable reward/risk
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟢 73
Looks like a real 'buy and hold for a decade' candidate
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟢 72
Growth candidate — the price hasn't caught up to the growth
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 59
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 52
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 48
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 45
No clear trend — Livermore preferred to stay out of this
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 39
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 29
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Based on the last 287 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (2 bullish · 7 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
-1315.4%
Net Margin
-1256.8%
EBITDA Margin
-1287.3%
ROE
-105.4%
ROA
-56.7%
ROIC
—
EPS
-$1.00
Cash
$152.41M
Total Debt
$32.53M
Current Ratio
8.41
Debt/Equity
0.26
How is Fair Value calculated? →
Current Price
$0.32
Estimated Fair Value (DCF)
-$26.55
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
⚠️ Extreme
Model output is extreme — likely a data/model limitation for this stock, not a reliable fair-value read.
Year 1 Growth Rate
25.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 25.0% | $-174.66M | $-160.24M |
| 2 | 19.4% | $-208.50M | $-175.49M |
| 3 | 13.8% | $-237.17M | $-183.14M |
| 4 | 8.1% | $-256.44M | $-181.67M |
| 5 | 2.5% | $-262.85M | $-170.83M |
Base FCF (last actual year)
$-139.73M
Terminal Value
$-4.14B
Present Value of Terminal Value
$-2.69B
Enterprise Value
$-3.57B
Net Debt
$-119.87M
Equity Value
$-3.45B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$0.95
Tangible Book Value per Share (Tangible NAV)
$0.95
Sentiment based on basic keywords (not AI) — 5 positive, 10 neutral, 5 negative out of the last 20 articles.
ChartMill · 8.9.2026
Benzinga · 8.9.2026
SeekingAlpha · 4.9.2026
Yahoo · 4.9.2026
BioPharma Dive · 4.9.2026
Benzinga · 3.9.2026
ChartMill · 2.9.2026
ChartMill · 2.9.2026
ChartMill · 2.9.2026
Benzinga · 2.9.2026
Yahoo · 2.9.2026
InvestorsHub · 2.9.2026
SeekingAlpha · 2.9.2026
Benzinga · 2.9.2026
Benzinga · 2.9.2026
Yahoo · 2.9.2026
GlobeNewswire · 2.9.2026
Benzinga · 2.9.2026
Yahoo · 26.8.2026
Simply Wall St. · 26.8.2026
TScan Therapeutics, Inc. (TCRX) currently has a StockIQ AI score of 43/100, rated "Weak". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
TCRX currently scores 43/100 (Weak) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
TCRX's technical score is 29/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Revenue growth (last year): 266.7%; Operating margin is stable or improving over time; Debt/equity: 0.26.
Based on the real signals StockIQ computed: Operating margin: -1315.4% (negative); Net margin: -1256.8% (negative); ATR: 13.6% of price.
StockIQ has no recorded dividend payment history for TCRX.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 2 purchases and 0 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | Grant/Award from Employer | 20.5.2026 | 67,000 | +67,000 | — |
| Nicholson Garry A | Grant/Award from Employer | 20.5.2026 | 67,000 | +67,000 | — |
| BAKER BROS. ADVISORS LP | Grant/Award from Employer | 20.5.2026 | 67,000 | +67,000 | — |
| Dorton Katina | Grant/Award from Employer | 20.5.2026 | 67,000 | +67,000 | — |
| Klencke Barbara | Grant/Award from Employer | 20.5.2026 | 67,000 | +67,000 | — |
| Gruia Gabriela | Grant/Award from Employer | 20.5.2026 | 67,000 | +67,000 | — |
| Woods Keith | Grant/Award from Employer | 20.5.2026 | 67,000 | +67,000 | — |
| BAKER JULIAN | Grant/Award from Employer | 20.5.2026 | 67,000 | +67,000 | — |
| Dorton Katina | Grant/Award from Employer | 20.5.2026 | 67,000 | +67,000 | — |
| Nicholson Garry A | Grant/Award from Employer | 20.5.2026 | 67,000 | +67,000 | — |
| Klencke Barbara | Grant/Award from Employer | 20.5.2026 | 67,000 | +67,000 | — |
| Gruia Gabriela | Grant/Award from Employer | 20.5.2026 | 67,000 | +67,000 | — |
| Woods Keith | Grant/Award from Employer | 20.5.2026 | 67,000 | +67,000 | — |
| Louis Chrystal | Grant/Award from Employer | 20.1.2026 | 420,000 | +420,000 | — |
| MacBeath Gavin | Grant/Award from Employer | 20.1.2026 | 1,165,000 | +1,165,000 | — |
| ZDRAVESKI ZORAN | Grant/Award from Employer | 20.1.2026 | 350,000 | +350,000 | — |
| Dworak Leiden | Grant/Award from Employer | 20.1.2026 | 100,000 | +100,000 | — |
| Amello Jason | Grant/Award from Employer | 20.1.2026 | 350,000 | +350,000 | — |
| Amello Jason | Grant/Award from Employer | 20.1.2026 | 350,000 | +350,000 | — |
| MacBeath Gavin | Grant/Award from Employer | 20.1.2026 | 1,165,000 | +1,165,000 | — |
| ZDRAVESKI ZORAN | Grant/Award from Employer | 20.1.2026 | 350,000 | +350,000 | — |
| Louis Chrystal | Grant/Award from Employer | 20.1.2026 | 420,000 | +420,000 | — |
| Dworak Leiden | Grant/Award from Employer | 20.1.2026 | 100,000 | +100,000 | — |
| Lynx1 Capital Management LP | Open Market Purchase | 23.12.2025 | 6,232 | +6,232 | $0.90 |
| Nichols Weston | Open Market Purchase | 23.12.2025 | 8,019,148 | +6,232 | $0.90 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
2,280,163 shares short as of 2026-09-15 · vs. 1,749,828 on 2026-08-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
37.5% of trading volume this week was short selling, vs. 46.4% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology